361346-46-5

Basic information

• Product Name: 3-Pyrrolidinamine, N,N-dimethyl-1-(4-nitrophenyl)-
• CAS NO: 361346-46-5
• Molecular Formula: C12H17N3O2
• Molecular Weight: 235.286
• Mol File: 361346-46-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-Pyrrolidinamine, N,N-dimethyl-1-(4-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyrrolidinamine, N,N-dimethyl-1-(4-nitrophenyl)-(361346-46-5)
• EPA Substance Registry System: 3-Pyrrolidinamine, N,N-dimethyl-1-(4-nitrophenyl)-(361346-46-5)

Safety Data

• Hazardous Substances Data: 361346-46-5(Hazardous Substances Data)

Upstream product

• 53779-90-1 dimethylaminopyrrolidine 
• 350-46-9 4-Fluoronitrobenzene 
• 69478-75-7 dimethyl-pyrrolidin-3-yl-amine 

Downstream Products

• 748183-91-7 6-chloro-N-[4-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]-nicotinamide 
• 686709-51-3 1-(4-aminophenyl)-N,N-dimethylpyrrolidin-3-amine 

Relevant articles and documents

COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS

The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER

The present invention encompasses compounds of general formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

Dyeing compositions for keratinous fibres containing paraphenylenediamine derivatives with pyrrolidinyl group

The invention concerns novel dyeing compositions for keratinous fibers comprising at least a paraphenylenediamine derivative with pyrrolidinyl group as oxidation base, a dyeing method and a dyeing kit using said composition.